Compounds > silybin
Page last updated: 2024-08-23

silybin and Disease Exacerbation

silybin has been researched along with Disease Exacerbation in 11 studies

Research

Studies (11)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's6 (54.55)29.6817
2010's4 (36.36)24.3611
2020's1 (9.09)2.80

Authors

AuthorsStudies
Bae, SW; Jang, KJ; Jo, ES; Kang, DY; Lee, JM; Rugamba, A; Sp, N1
Cheng, Y; Guan, Z; Jiang, Y; Li, Q; Sun, Y; Xu, Y; Zhao, W1
Flaig, TW; Goyal, A; Greenlee, H; Gustafson, DL; Hansen, RJ; Jacobson, JS; Kelly, K; Ladas, E; Lee, V; Lunghofer, PJ; Narayan, R; Rodriguez, R; Siegel, AB; Tsai, WY; Wu, DP1
Bouderba, S; Detaille, D; Koceïr, EA; Sanchez-Martin, C; Villanueva, GR1
Agarwal, R; Chittezhath, M; Deep, G; Raina, K; Rajamanickam, S; Singh, RP1
Agarwal, R; Raina, K; Sharma, G; Singh, RP1
Brandon-Warner, E; Eheim, AL; Foureau, DM; McKillop, IH; Schrum, LW; Walling, TL1
Agarwal, C; Agarwal, R; Chan, DC; Singh, RP; Tyagi, AK1
Chen, PN; Chu, SC; Hsieh, YS; Liu, YC; Lu, KH; Yang, SF1
Capasso, R; D'Auria, MV; de Sio, I; Del Vecchio Blanco, C; Di Leva, A; Federico, A; Loguercio, C; Niosi, M; Trappoliere, M; Tuccillo, C1
Agarwal, R; Blouin, MJ; Cohen, P; Deep, G; Glodé, LM; Greenberg, NM; Hwang, D; Majeed, N; Pollak, MN; Raina, K; Singh, RP; Varghese, L1

Trials

1 trial(s) available for silybin and Disease Exacerbation

ArticleYear
A phase I dose-finding study of silybin phosphatidylcholine (milk thistle) in patients with advanced hepatocellular carcinoma.
    Integrative cancer therapies, 2014, Volume: 13, Issue:1

    Topics: Antioxidants; Carcinoma, Hepatocellular; Disease Progression; Dose-Response Relationship, Drug; Humans; Liver Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Phosphatidylcholines; Silybin; Silybum marianum; Silymarin

2014

Other Studies

10 other study(ies) available for silybin and Disease Exacerbation

ArticleYear
Silibinin Regulates Tumor Progression and Tumorsphere Formation by Suppressing PD-L1 Expression in Non-Small Cell Lung Cancer (NSCLC) Cells.
    Cells, 2021, 06-29, Volume: 10, Issue:7

    Topics: Apoptosis; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Progression; ErbB Receptors; Human Umbilical Vein Endothelial Cells; Humans; Lung Neoplasms; Models, Biological; Neoplasm Invasiveness; Neoplastic Stem Cells; Neovascularization, Physiologic; Promoter Regions, Genetic; Protein Binding; Silybin; Spheroids, Cellular; STAT5 Transcription Factor

2021
Silibinin suppresses bladder cancer cell malignancy and chemoresistance in an NF-κB signal-dependent and signal-independent manner.
    International journal of oncology, 2017, Volume: 51, Issue:4

    Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Cell Growth Processes; Cell Line, Tumor; Cell Movement; Cisplatin; Disease Progression; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Humans; Neoplasm Invasiveness; NF-kappa B; Signal Transduction; Silybin; Silymarin; Urinary Bladder Neoplasms

2017
Beneficial effects of silibinin against the progression of metabolic syndrome, increased oxidative stress, and liver steatosis in Psammomys obesus, a relevant animal model of human obesity and diabetes.
    Journal of diabetes, 2014, Volume: 6, Issue:2

    Topics: Animals; Antioxidants; Blood Glucose; Diabetes Mellitus, Type 2; Disease Models, Animal; Disease Progression; Fatty Liver; Gerbillinae; Glutathione; Glutathione Peroxidase; Humans; Insulin; Lipids; Liver; Metabolic Syndrome; Obesity; Oxidative Stress; Silybin; Silymarin; Superoxide Dismutase

2014
Stage-specific inhibitory effects and associated mechanisms of silibinin on tumor progression and metastasis in transgenic adenocarcinoma of the mouse prostate model.
    Cancer research, 2008, Aug-15, Volume: 68, Issue:16

    Topics: Adenocarcinoma; Animals; Antioxidants; Apoptosis; Biomarkers, Tumor; Blotting, Western; Body Weight; Cell Cycle Proteins; Cell Movement; Cell Proliferation; Disease Models, Animal; Disease Progression; Female; Humans; Immunoenzyme Techniques; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Mice; Mice, Inbred C57BL; Mice, Nude; Mice, Transgenic; Neoplasm Staging; Neovascularization, Pathologic; Nitric Oxide Synthase Type II; Prostate; Prostatic Intraepithelial Neoplasia; Prostatic Neoplasms; Silybin; Silybum marianum; Silymarin; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays

2008
Silibinin inhibits established prostate tumor growth, progression, invasion, and metastasis and suppresses tumor angiogenesis and epithelial-mesenchymal transition in transgenic adenocarcinoma of the mouse prostate model mice.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Dec-01, Volume: 14, Issue:23

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Blotting, Western; Cadherins; Cell Proliferation; Disease Progression; Immunohistochemistry; Male; Matrix Metalloproteinases; Mice; Mice, Transgenic; Neoplasm Metastasis; Neovascularization, Pathologic; Prostatic Neoplasms; Silybin; Silymarin; Vimentin

2008
Silibinin (Milk Thistle) potentiates ethanol-dependent hepatocellular carcinoma progression in male mice.
    Cancer letters, 2012, Dec-29, Volume: 326, Issue:1

    Topics: Alcohol Drinking; Animals; Antioxidants; Carcinoma, Hepatocellular; Cell Proliferation; Dietary Supplements; Disease Progression; Ethanol; Female; Liver Neoplasms; Male; Mice; Sex Characteristics; Silybin; Silybum marianum; Silymarin; Tumor Burden

2012
Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth Inhibition, G2-M arrest, and apoptosis.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2002, Volume: 8, Issue:11

    Topics: Animals; Annexin A5; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; CDC2 Protein Kinase; Cell Cycle; Cell Division; Cell Separation; Disease Progression; Doxorubicin; Flow Cytometry; G2 Phase; Humans; Male; Mice; Mice, Nude; Mitosis; Neoplasm Transplantation; Prostatic Neoplasms; Silybin; Silymarin; Tumor Cells, Cultured

2002
Silibinin suppresses human osteosarcoma MG-63 cell invasion by inhibiting the ERK-dependent c-Jun/AP-1 induction of MMP-2.
    Carcinogenesis, 2007, Volume: 28, Issue:5

    Topics: Bone Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Shape; Cell Survival; Disease Progression; Extracellular Signal-Regulated MAP Kinases; Focal Adhesion Kinase 1; Humans; Male; Matrix Metalloproteinase 2; Neoplasm Invasiveness; Osteosarcoma; Proto-Oncogene Proteins c-jun; Signal Transduction; Silybin; Silymarin; Transcription Factor AP-1; Urokinase-Type Plasminogen Activator

2007
The effect of a silybin-vitamin e-phospholipid complex on nonalcoholic fatty liver disease: a pilot study.
    Digestive diseases and sciences, 2007, Volume: 52, Issue:9

    Topics: Adult; Aged; Antioxidants; Cytokines; Disease Progression; Drug Therapy, Combination; Fatty Liver; Female; Follow-Up Studies; Humans; Male; Middle Aged; Phospholipids; Pilot Projects; Silybin; Silybum marianum; Silymarin; Time Factors; Transaminases; Treatment Outcome; Ultrasonography; Vitamin E

2007
Dietary feeding of silibinin inhibits prostate tumor growth and progression in transgenic adenocarcinoma of the mouse prostate model.
    Cancer research, 2007, Nov-15, Volume: 67, Issue:22

    Topics: Adenocarcinoma; Animals; Anticarcinogenic Agents; Antioxidants; Disease Models, Animal; Disease Progression; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Phosphorylation; Prostate; Prostatic Neoplasms; Silybin; Silymarin; Species Specificity

2007